Naturally occurring reoviruses for human cancer therapy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Naturally occurring reoviruses are live replication-proficient viruses that specifically infect human cancer cells while sparing their normal counterpart. Since the discovery of reoviruses in 1950s, they have shown various degrees of safety and efficacy in pre-clinical or clinical applications for human anti-cancer therapeutics. I have recently discovered that cellular tumor suppressor genes are also important in determining reoviral tropism. Carcinogenesis is a multi-step process involving the accumulation of both oncogene and tumor suppressor gene abnormalities. Reoviruses can exploit abnormal cellular tumor suppressor signaling for their oncolytic specificity and efficacy. Many tumor suppressor genes such as p53, ataxia telangiectasia mutated (ATM), and retinoblastoma associated (RB) are known to play important roles in genomic fidelity/maintenance. Thus, a tumor suppressor gene abnormality could affect host genomic integrity and likely disrupt intact antiviral networks due to the accumulation of genetic defects which in turn could result in oncolytic reovirus susceptibility. This review outlines the discovery of oncolytic reovirus strains, recent progresses in elucidating the molecular connection between oncogene/tumor suppressor gene abnormalities and reoviral oncotropism, and their clinical implications. Future directions in the utility of reovirus virotherapy is also proposed in this review.
Abstract
Naturally occurring reoviruses are live replication-proficient viruses that specifically infect human cancer cells while sparing their normal counterpart. Since the discovery of reoviruses in 1950s, they have shown various degrees of safety and efficacy in pre-clinical or clinical applications for human anti-cancer therapeutics. I have recently discovered that cellular tumor suppressor genes are also important in determining reoviral tropism. Carcinogenesis is a multi-step process involving the accumulation of both oncogene and tumor suppressor gene abnormalities. Reoviruses can exploit abnormal cellular tumor suppressor signaling for their oncolytic specificity and efficacy. Many tumor suppressor genes such as p53, ataxia telangiectasia mutated (ATM), and retinoblastoma associated (RB) are known to play important roles in genomic fidelity/maintenance. Thus, a tumor suppressor gene abnormality could affect host genomic integrity and likely disrupt intact antiviral networks due to the accumulation of genetic defects which in turn could result in oncolytic reovirus susceptibility. This review outlines the discovery of oncolytic reovirus strains, recent progresses in elucidating the molecular connection between oncogene/tumor suppressor gene abnormalities and reoviral oncotropism, and their clinical implications. Future directions in the utility of reovirus virotherapy is also proposed in this review.
참고문헌 (48)
- 김만복, "Replicating poxviruses for human cancer therapy", The Journal of Microbiology, 53(4), pp.209~218 (2015), 한국미생물학회[DOI]
- Roberts MS, "Naturally oncolytic viruses", Curr Opin Mol Ther, 8, pp.314~321 (2006)
- Wang G, "Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor", Proc Natl Acad Sci U S A, 103, pp.4640~4645 (2006)
- Strong JE, "The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus", EMBO J, 17, pp.3351~3362 (1998)
- Kim M, "The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status", Oncogene, 29, pp.3990~3996 (2010)
- Tyler KL, "Fields Virology", pp.1729~1745 (2001), Lippincott-Raven
- Ramig RF, "Genome RNAs and polypeptides of reovirus serotypes 1, 2, and 3", J Virol, 22, pp.726~733 (1977)
- Stanley NF, "Studies on the pathogenesis of a hitherto undescribed virus(hepato-encephalomyelitis)producing unusual symptoms in suckling mice", Aust J Exp Biol Med Sci, 31, pp.147~159 (1953)
- Sabin AB., "A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described", Science, 130, pp.1387~1389 (1959)
- Stanley NF, "Relationship of Hepatoencephalomyelitis Virus and Reoviruses", letters to Nature, 189, pp.687~ (1961)
- Ramos-Alvarez M, "Characteristics of poliomyelitis and other enteric viruses recovered in tissue culture from healthy American children", Proc Soc Exp Biol Med, 87, pp.655~661 (1954)
- Stoeckel J, "Drug evaluation:Reolysin--wild-type reovirus as a cancer therapeutics", Curr Opin Mol Ther, 8, pp.249~260 (2006)
- Ramos-Alvarez M, "Enteropathogenic viruses and bacteria. Role in summer diarrheal diseases of infancy and early childhood", Jour Amer Med Ass'n, 167, pp.147~156 (1958)
- Jackson GG, "Reovirus type 1 as an etiologic agent of the common cold", Jour Clin Invest, 40, pp.1051~ (1961)
- Ramos-Alvarez M, "Intestinal viral flora of healthy children demonstrable by monkey kidney tissue culture", Amer Jour Pub Health, 46, pp.295~299 (1956)
- Rosen L, "Reovirus infections in human volunteers", Am J Hyg, 77, pp.29~37 (1963)
- Vidal L, "A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer", Clin Cancer Res, 14, pp.7127~7137 (2008)
- Bennette JG, "Isolation of a Non-pathogenic Tumour-destroying Virus from Mouse Ascites", Nature, 187, pp.72~73 (1960)
- Nelson JB, "An Oncolytic Virus recovered from Swiss Mice during Passage of an Ascites Tumour", Nature, 188, pp.866~867 (1960)
- Bennette JG, "Characteristics of a newborn runt disease induced by neonatal infection with an oncolytic strain of reovirus type 3(REO3MH). I. Pathological investigations in rats and mice", Br J Exp Pathol, 48, pp.251~266 (1967)
- Hashiro G, "The preferential cytotoxicity of reovirus for certain transformed cell lines", Arch Virol, 54, pp.307~315 (1977)
- Duncan MR, "Differential sensitivity of normal and transformed human cells to reovirus infection", J Virol, 28, pp.444~449 (1978)
- Strong JE, "The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus", EMBO J, 17, pp.3351~3362 (1998)
- Coffey MC, "Reovirus therapy of tumors with activated Ras pathway", Science, 282, pp.1332~1334 (1998)
- 김만복, "Reovirus and Tumor Oncolysis", The Journal of Microbiology, 45(3), pp.187~192 (2007), 한국미생물학회
- Kuttler F, "c-Myc, Genomic Instability and Disease", Genome Dyn, 1, pp.171~190 (2006)
- Prochownik EV, "The ever expanding role for c-Myc in promoting genomic instability", Cell Cycle, 6, pp.1024~1029 (2007)
- Prochownik EV, "c-Myc : linking transformation and genomic instability", Curr Mol Med, 8, pp.446~458 (2008)
- Coschi CH, "Chromosome instability and deregulated proliferation: an unavoidable duo", Cell Mol Life Sci, 69, pp.2009~2024 (2012)
- Holohan C, "Cancer drug resistance: an evolving paradigm", Nat Rev Cancer, 13, pp.714~726 (2013)
- Kim M, "Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells", Oncogene, 26, pp.4124~4134 (2007)
- Alain T, "The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro", Br J Cancer, 95, pp.1020~1027 (2006)
- Loken SD, "Morbidity in immunosuppressed(SCID", NOD)mice treated with reovirus(dearing 3)as an anticancer biotherapeutics, 2004, pp.3, 734~738
- Kim M, "Attenuated reovirus displays oncolysis with reduced host toxicity", Br J Cancer, 104, pp.290~299 (2011)
- Kim M, "Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy", Chinese patent No.: 200980126543.5, ~ (2014)
- Lolkema MP, "A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer", Clin Cancer Res, 17, pp.581~588 (2011)
- Comins C, "REO-10 : a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer", Clin Cancer Res, 16, pp.5564~5572 (2010)
- Alloussi SH, "All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma", Oncol Rep, 26, pp.645~649 (2011)
- Minuk GY, "The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease", J Med Virol, 16, pp.55~60 (1985)
- Minuk GY, "Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis", J Hepatol, 5, pp.8~13 (1987)
- Le Boeuf F, "Synergistic interaction between oncolytic viruses augments tumor killing", Mol Ther, 18, pp.888~895 (2010)
- Alkassar M, "The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo", J Neurooncol, 104, pp.715~727 (2011)
- Forsyth P, "A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas", Mol Ther, 16, pp.627~632 (2008)
- Karapanagiotou EM, "Phase I", II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies, 2012, pp.18, 2080~2089
- Galanis E, "Phase II trial of intravenous administration of Reolysin(®)(Reovirus Serotype-3-dearing Strain)in patients with metastatic melanoma", Mol Ther, 20, pp.1998~2003 (2012)
- Morris DG, "REO-001 : A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing(Reolysin®)in patients with advanced solid tumors", Invest New Drugs, 31, pp.696~706 (2013)
- Harrington KJ, "Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers", Clin Cancer Res, 16, pp.3067~3077 (2010)
- Kicielinski KP, "Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults", Mol Ther, 22, pp.1056~1062 (2014)